Abstract:PRRT2 mutations are common in patients with PKD and are significantly associated with an earlier age at onset, longer duration of attacks, a complicated form of PKD, combined phenotypes of dystonia and chorea, and a tendency for a family history of PKD. A patient with uniparental disomy resulting in a homozygous c.931C>T mutation is identified in the present study. Carbamazepine is the first-choice drug for patients with PKD, but an individualized treatment regimen should be developed.
“…8 Neuroimaging of PKD-D, PKD-C or a mixture of both types has also failed to completely define specific neural characteristics that allow differentiation between these disorders. 9,10 At present, diagnosis of PKD mainly relies on these clinical characteristics, in the absence of reliable PKD-D- or PKD-C-specific neuromarkers.…”
The neurobiological basis of paroxysmal kinesigenic dyskinesia (PKD) is poorly defined due to the lack of reliable neuroimaging differences that can distinguish PKD with dystonia (PKD-D) from PKD with chorea (PKD-C). Consequently, diagnosis of PKD remains largely based on the clinical phenotype. Understanding the pathophysiology of PKD may facilitate discrimination between PKD-D and PKD-C, potentially contributing to more accurate diagnosis.We conducted resting-state functional magnetic resonance imaging on patients with PKD-D (n = 22), PKD-C (n = 10), and healthy controls (n = 32). Local synchronization was measured in all 3 groups via regional homogeneity (ReHo) and evaluated using receiver operator characteristic analysis to distinguish between PKD-C and PKD-D.Cortical-basal ganglia circuitry differed significantly between the 2 groups at a specific frequency. Furthermore, the PKD-D and PKD-C patients were observed to show different spontaneous brain activity in the right precuneus, right putamen, and right angular gyrus at the slow-5 frequency band (0.01–0.027 Hz).The frequency-specific abnormal local synchronization between the 2 types of PKD offers new insights into the pathophysiology of this disorder to some extent.
“…8 Neuroimaging of PKD-D, PKD-C or a mixture of both types has also failed to completely define specific neural characteristics that allow differentiation between these disorders. 9,10 At present, diagnosis of PKD mainly relies on these clinical characteristics, in the absence of reliable PKD-D- or PKD-C-specific neuromarkers.…”
The neurobiological basis of paroxysmal kinesigenic dyskinesia (PKD) is poorly defined due to the lack of reliable neuroimaging differences that can distinguish PKD with dystonia (PKD-D) from PKD with chorea (PKD-C). Consequently, diagnosis of PKD remains largely based on the clinical phenotype. Understanding the pathophysiology of PKD may facilitate discrimination between PKD-D and PKD-C, potentially contributing to more accurate diagnosis.We conducted resting-state functional magnetic resonance imaging on patients with PKD-D (n = 22), PKD-C (n = 10), and healthy controls (n = 32). Local synchronization was measured in all 3 groups via regional homogeneity (ReHo) and evaluated using receiver operator characteristic analysis to distinguish between PKD-C and PKD-D.Cortical-basal ganglia circuitry differed significantly between the 2 groups at a specific frequency. Furthermore, the PKD-D and PKD-C patients were observed to show different spontaneous brain activity in the right precuneus, right putamen, and right angular gyrus at the slow-5 frequency band (0.01–0.027 Hz).The frequency-specific abnormal local synchronization between the 2 types of PKD offers new insights into the pathophysiology of this disorder to some extent.
“…In previous studies, point and frameshift mutations in PRRT2 were identified in 61.5%–100% of familial cases of PKD (Huang et al, 2015; Liu et al, 2013). Even in sporadic cases, the majority point and frameshift mutations of PRRT2 were inherited from unaffected parents (Ebrahimi‐Fakhari, Saffari, Westenberger, & Klein, 2015).…”
Section: Discussionmentioning
confidence: 93%
“…PRRT2 is the most common causative gene for PKD. Mutations of PRRT2 , including point mutations and frameshift mutations, explain approximately less than one‐half of PKD cases (Huang et al, 2015), suggesting the presence of additional molecular pathogenic mechanisms. In this study, PRRT2 CNVs were identified in two patients with PKD, indicating that copy number deletion of PRRT2 is also a potential pathogenic factor for the disease.…”
Section: Discussionmentioning
confidence: 99%
“…PRRT2 is the most common known causative gene for PKD. Point and frameshift mutations in PRRT2 account for 20.8%–48.4% of cases with PKD (Huang et al, 2015; Liu et al, 2013; Youn et al, 2014). Clinically, PKD cases with negative genetic findings are not rare, especially the sporadic cases (Wang et al, 2016).…”
IntroductionMutations of the PRRT2 gene are the most common cause for paroxysmal kinesigenic dyskinesia. However, patients with negative PRRT2 mutations are not rare. The aim of this study is to determine whether copy number variant of PRRT2 gene is another potential pathogenic mechanism in the patients with paroxysmal kinesigenic dyskinesia with negative PRRT2 point and frameshift mutations.MethodsWe screened PRRT2 copy number variants using the AccuCopy™ method in 29 patients with paroxysmal kinesigenic dyskinesia with negative PRRT2 point and frameshift mutations. Next‐generation sequencing was used to determine the chromosomal deletion sites in patients with PRRT2 copy number variants, and to exclude mutations in other known causative genes for paroxysmal kinesigenic dyskinesia.ResultsTwo sporadic patients with negative PRRT2 point and frameshift mutations (6.9%) were identified to have de novo PRRT2 copy number deletions (591 and 832 Kb deletions located in 16p11.2). The two patients presented with pure paroxysmal kinesigenic dyskinesia and paroxysmal kinesigenic dyskinesia and benign infantile convulsions, respectively. They had normal intelligence and neuropsychiatric development, in contrast to those previously reported with 16p11.2 deletions complicated with neuropsychiatric disorders. No correlation between the deletion ranges and phenotypic variations was found.Conclusion16p11.2 deletions play causative roles in paroxysmal kinesigenic dyskinesia, especially for sporadic cases. Our findings extend the phenotype of 16p11.2 deletions to pure paroxysmal kinesigenic dyskinesia. Screening for 16p11.2 deletions should thus be included in genetic evaluations for patients with paroxysmal kinesigenic dyskinesia.
“…먼저 (Yuan et al, 2012;Bae et al, 2011;Gao et al, 2011;Pech et al, 2010;Kaempgen et al, 2009;In et al, 2006 (Ning et al, 2016;Pei et al, 2016;Huang et al, 2015;Ramadoss and Kim, 2014 (Choi, et al, 2012;Li, et al, 2011;Chen, et al, 2010). …”
The MnO 2 electrodeposited on the surface of the carbon nanofiber mats (MnO 2 -LCNFM) were prepared from electrospun lignin-g-PAN copolymer via heat treatments and subsequent MnO 2 electrodeposition method. The resulting MnO 2 -LCNFM was evaluateed for its potential use in a supercapicitor electrode. The increase of MnO 2 electric deposition time was revealed to increase diameter of carbon nanofibers as well as MnO 2 content on the surface of carbon nanofiber mats as confirmed by scanning electon microscope (SEM) analysis. The electrochemical properties of MnO 2 -LCNFM electrodes are evaluated through cyclic voltammetry test. It was shown that MnO 2 -LCNFM electrode exhibited good electrochemical performance with specific capacitance of 168.0 mF⋅cm -2 . The MnO 2 -LCNFM supercapacitor successfully fabricated using the gel electrolyte (H 3 PO 4 /Polyvinyl alcohol) showed to have the capacitance efficiency of ∼90%, and stable behavior during 1,000 charging/discharging cycles.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.